February 29, 2024LeukemiaOpen Access

Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance

View Full Paper

Ask AI

Bookmark

Authors

SCSimone ClaudianiImperial College Healthcare NHS Trust FCFarhan ChughtaiImperial College London AKAfzal KhanImperial College Healthcare NHS Trust

Discussion

Member takes

Implication

Retrospective analysis reveals distinct survival outcomes following second-generation tyrosine kinase inhibitor failure in chronic myeloid leukemia, highlighting the need for tailored therapy.

Key Points

Deep molecular responses occurred in most patients on initial therapy, but resistance to second-generation tyrosine kinase inhibitors led to substantially inferior long-term survival.
Seven-year overall survival reached only 66.1% among resistant individuals, whereas intolerant patients sustained 100% survival after switching to alternative tyrosine kinase inhibitors.
Analysis of 106 chronic myeloid leukemia cases demonstrates that upfront treatment failure requires early transition to third-generation tyrosine kinase inhibitors or stem cell transplant.

Cite This Study

Claudiani et al. (2024) studied this question.

synapsesocial.com/papers/68e76cf5b6db6435876e2a17 https://doi.org/10.1038/s41375-024-02187-w

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reveals distinct survival outcomes following second-generation tyrosine kinase inhibitor failure in chronic myeloid leukemia, highlighting the need for tailored therapy.

Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance

Discussion

Member takes

Implication

Key Points

Cite This Study

Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider